rifampicine bij longontsteking vermindert de ontstekingsreactie

• Conditions: Community acquired pneumonia CURB-65 class >1; MedDRA version: 14.1Level: LLTClassification code 10010120Term: Community acquired pneumoniaSystem Organ Class: 100000004862; Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

• Registration Number: EUCTR2012-003067-22-NL
• Lead Sponsor: MC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-11-19
• Last Update Posted: 3 December 2012

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1.Patient aged 18 years or above
2.Community acquired pneumonia with CURB65 score = 2

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 20
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 20

Exclusion Criteria

•Known allergy to rifampicin or anaemia or thrombopenia as side effect of rifampicin in medical history
•Medication induced hepatitis or acute liver failure
•Porphyria
•????Renal failure with creatinin clearance < 25 ml/min
•Use of voriconazol or protease inhibitors
health care associated pneumonia
•Female patients who are pregnant
•Lung transplant recipients

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified